Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 74 of 144 pages ‹ First < 72 73 74 75 76 > Last ›
HSL19032
Herndon MB, Schwartz LM, Woloshin S, Welch HG.
Implications of expanding disease definitions: the case of osteoporosis.
Health Aff (Millwood) 2007; 26:(6):1702-11
http://content.healthaffairs.org/content/26/6/1702.long
HSL19031
Welch HG, Woloshin S, Schwartz LM, Gordis L, Gøtzsche PC, Harris R, Kramer BS, Ransohoff DF.
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study.
Arch Intern Med 2007 26; 167:(21):2289-95
http://archinte.ama-assn.org/cgi/content/full/167/21/2289
HSL7214
Cohen D.
Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?
Psychother Psychosom 2007; 76:(1):5-14
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000096360
HSL7389
Hurley D.
Modern Snake Oil? NATURAL CAUSES: Death, Lies, and Politics in America's Vitamin and Herbal Supplement Industry
: Broadway 2007
http://www.businessweek.com/magazine/content/07_02/b4016109.htm
HSL7451
US FDA
FDA's Electronic Freedom of Information Reading Room - Warning Letters and Responses
Rockville, MD: US FDA 2007
http://www.fda.gov/foi/warning.htm
HSL7587
Dowden JS.
Product information past perfect
Med J Aust 2007; 186:(2):51-52
http://www.mja.com.au/public/issues/186_02_150107/dow11056_fm.html
HSL7588
Stockigt JR.
Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medications
Med J Aust 2007; 186:(2):76-79
http://www.mja.com.au/public/issues/186_02_150107/sto10229_fm.html
HSL8017
Du W, Levine M, Wang L, Zhang Y, Yi C, Wang H, Wang X, Xie H, Xu J, Jin H, Wang T, Huang G, Wu Y.
Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
Can J Clin Pharmacol 2007 Win; 14:(1):e40-4
http://www.cjcp.ca/pdf/CJCP2007_e40_e44.pdf
HSL8065
Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK.
Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-Consumer Advertising
Annals of Family Medicine 2007; 5:6-13
http://www.annfammed.org/cgi/content/full/5/1/6
HSL8206
Kessler DA.
Direct-to-Consumer Advertising: Is It Too Late to Manage the Risks?
Annals of Family Medicine 2007; 5:(1):4-5
http://www.annfammed.org/cgi/content/full/5/1/4
HSL8208
Stange KC.
In This Issue: Doctor-Patient and Drug Company-Patient Communication
Annals of Family Medicine 5:2-4 (2007) 2007; 5:(1):2-4
http://www.annfammed.org/cgi/content/full/5/1/2
HSL8209
Goodman RL.
Medical education and the pharmaceutical industry.
Perspect Biol Med 2007 Win; 50:(1):32-9
http://www.ncbi.nlm.nih.gov/pubmed/17259674
HSL8210
Moffatt B, Elliott C.
Ghost marketing: pharmaceutical companies and ghostwritten journal articles.
Perspect Biol Med 2007 Win; 50:(1):18-31
http://muse.jhu.edu/cgi-bin/access.cgi?uri=/journals/perspectives_in_biology_and_medicine/v050/50.1moffatt.html
HSL8247
Fleg AN.
Introduction to pharmaceuticology
studentBMJ 2007; 15:45-88
http://www.studentbmj.com/issues/07/02/life/78.php
HSL8248
Bernal L.
Why Pharma Must Go Hollywood
The Scientist 2007; 21:(2):42
http://www.the-scientist.com/2007/2/1/42/1/
HSL8678
Koren G, MacLeod S, Davis D.
Drugs in pregnancy: acknowledging challenges--finding solutions.
Can J Clin Pharmacol 2007 Win; 14:(1):e2-4
http://www.cjcp.ca/pdf/CJCP2007_e2_e4.pdf
HSL8679
Finkelstein Y, Rezvani M, Garcia-Bournissen F, Nurmohamed L, Koren G.
Inactive pharmaceutical ingredients : implications for pregnancy.
Can J Clin Pharmacol 2007 Win; 14:(1):e17-28
http://www.cjcp.ca/pdf/CJCP2007_e17_e28.pdf
HSL8749
Maggioni AP, Darne B, Atar D, Abadie E, Pitt B, Zannad F; 5th Cardiovascular Clinical Trialists Workshop.
FDA and CPMP rulings on subgroup analyses.
Cardiology 2007; 107:(2):97-102
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowFulltext&ArtikelNr=94508&Ausgabe=232050&ProduktNr=223832
HSL8768
Lewis WR.
Pros and cons of the pharmaceutical industry and education.
Prev Cardiol 2007 Winter; 10:(1):5-6
http://www.lejacq.com/Search_articleDetail.cfm?aid=PC5977%2DLewis%2Epdf&CFID=1869878&CFTOKEN=77879140
HSL8822
Brody H.
Hooked: Ethics, the Medical Profession and the Pharmaceutical Industry.
Lanham, MD: Rowman & Littlefield 2007
http://web.archive.org/web/20070429232434/http://www.rowmanlittlefield.com/Catalog/SingleBook.shtml?command=Search&db=%5EDB/CATALOG.db&eqSKUdata=0742552195&thepassedurl=[thepassedurl]
HSL8911
BUKO Pharma-Kampagne
Counterfeit medicines – what are the problems?
Bielefeld, Germany: BUKO Pharma-Kampagne 2007
http://www.bukopharma.de/Service/Archiv/E2007_01_special.pdf
HSL8962
Stossel TP.
Regulation of financial conflicts of interest in medical practice and medical research: a damaging solution in search of a problem.
Perspect Biol Med 2007 Win; 50:(1):54-71
http://muse.jhu.edu/login?uri=/journals/perspectives_in_biology_and_medicine/v050/50.1stossel.html
HSL9015
Day RO, Williams KM.
Open-label extension studies: do they provide meaningful information on the safety of new drugs?
Drug Saf 2007; 30:(2):93-105
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17253876&query_hl=6&itool=pubmed_DocSum
HSL9363
Clark RC, Maxwell SR, Kerr S, Cuthbert M, Buchanan D, Steinke D, Webb DJ, Bateman ND.
The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.
Drug Saf 2007; 30:(4):357-66
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17408312&query_hl=10&itool=pubmed_docsum
HSL19381
Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M.
Adding or switching antipsychotic medications in treatment-refractory schizophrenia.
Psychiatr Serv 2007; 58:(7):983-90
http://ps.psychiatryonline.org/cgi/content/full/58/7/983
HSL9819
Zaghi D, Maibach HI.
Survey of safety and efficacy information in drug inserts for topical prescription medications.
Am J Clin Dermatol 2007; 8:(1):43-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17298106&query_hl=19&itool=pubmed_DocSum
HSL9996
Amoresano GV.
Branded drug reformulation: the next brand vs. generic antitrust battleground
Food Drug Law J. 2007; 62:(1):249-56
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17444032&query_hl=1&itool=pubmed_DocSum
HSL9997
Kendrick LC.
FDA's regulation of prescription drug labeling: a role for implied preemption.
Food Drug Law J 2007; 62:(1):227-47
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17444031&query_hl=2&itool=pubmed_DocSum
HSL9998
Hall RF, Sobotka E.
Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
Food Drug Law J 2007; 62:(1):1-48
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17444025&query_hl=3&itool=pubmed_DocSum
HSL10004
Lerner BH.
Ill patient, public activist: Rose Kushner's attack on breast cancer chemotherapy.
Bull Hist Med 2007 Spr; 81:(1):224-40
http://muse.jhu.edu/login?uri=/journals/bulletin_of_the_history_of_medicine/v081/81.1lerner.html
HSL10008
Schwartz MB, Brownell KD.
Actions necessary to prevent childhood obesity: creating the climate for change.
J Law Med Ethics 2007 Spr; 35:(1):78-89
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1748-720X.2007.00114.x
HSL10009
Schor JB, Ford M.
From tastes great to cool: children's food marketing and the rise of the symbolic.
J Law Med Ethics 2007 Spr; 35:(1):10-21
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1748-720X.2007.00110.x
HSL10014
Chauhan D, Miners AH, Fischer AJ.
Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
Int J Technol Assess Health Care 2007 Win; 23:(1):96-100
http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=651536
HSL10015
Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J.
Assessing the economic challenges posed by orphan drugs.
Int J Technol Assess Health Care 2007 Win; 23:(1):36-42
http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=651480
HSL10023
Guyatt G, Devereaux PJ, Lexchin J, Stone SB, Yalnizyan A, Himmelstein D, Woolhandler S, Zhou Q, Goldsmith G, Cook DJ, Haines T, Lacchetti C, Lavis J, Sullivan T, Mills E, Kraus S, Bhatnagar N.
A systematic review of studies comparing health outcomes in Canada and the United States
Open Medicine 2007; 1:(1):E27-36
http://www.openmedicine.ca/article/view/8/1
HSL10031
Taylor CR, Capella ML, Kozup JC.
Does DTC Advertising Provide Information or Create Market Power? Evidence from the U.S. and New Zealand
Advances in International Marketing 2007; 18:9-30
HSL10032
Diehl S, Mueller B, Terlutter R.
Skepticism Toward Pharmaceutical Advertising in the U.S. and Germany
Advances in International Marketing 2007; 18:31-60
HSL10053
Zhang Y, Soumerai SB.
Do newer prescription drugs pay for themselves? A reassessment of the evidence
Health Affairs 2007;
http://content.healthaffairs.org/cgi/content/full/26/3/880
HSL10069
Kassirer JP.
Joint ownership: the shared responsibilities of journal editors and publishers.
Md Med 2007 Win; 8:(1):10-2
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17472146&query_hl=2&itool=pubmed_DocSum
HSL10070
Hoey J.
Is editorial freedom vanishing?
Md Med 2007 Win; 8:(1):8-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17472145&query_hl=3&itool=pubmed_DocSum
HSL10143
Canadian Pharmacists Association
Safe and Effective: The Eight Essential Elements of an Optimal Medication-Use System
: Canadian Pharmacists Association 2007
http://www.pharmacists.ca/function/shopper/ProductDetail.cfm?ProdCompanyPassed=cpa&ProdCdPassed=cpa-27024-1&PriceCategPassed=std&indexstart=1
HSL10586
Groopman J.
How Doctors Think
: Houghton & Mifflin 2007
http://www.houghtonmifflinbooks.com/catalog/titledetail.cfm?titleNumber=689664
HSL10681
Racine E, van der Loos HZ, Illes J.
Internet marketing of neuroproducts: new practices and healthcare policy challenges.
Camb Q Healthc Ethics 2007 Spr; 16:(2):181-94
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17539470&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSumhttp://
HSL10880
Mastin T, Andsager JL, Choi J, Lee K.
Health Disparities and Direct-to-Consumer Prescription Drug Advertising: A Content Analysis of Targeted Magazine Genres, 1992-2002.
Health Commun 2007; 22:(1):49-58
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17617013&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL10895
Copper BK.
Notes and comments 'High and dry?' The Public Readiness and Emergency Preparedness Act and liability protection for pharmaceutical manufacturers.
J Health Law 2007; 40:(1):65-105
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17549932&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL10898
Jaquette I.
Merck KGaA v Integra Lifesciences I, Ltd: implications of the supreme court's decision for the people who matter most ...the consumer.
Am J Law Med 2007; 33:(1):97-117
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17547356&dopt=Abstract
HSL10951
Newhouse JP, Seiguer E, Frank RG.
Was Part D a giveaway to the pharmaceutical industry?
Inquiry 2007 Spr; 44:(1):15-25
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17583259&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL10964
Siekmeier R, Lutz J.
Experience with post-market surveillance of in-vitro diagnostic medical devices for lay use in Germany.
Clin Chem Lab Med 2007; 45:(3):396-401
http://www.atypon-link.com/doi/abs/10.1515/CCLM.2007.058
HSL10966
Kim CH.
The case for preemption of prescription drug failure-to-warn claims.
Food Drug Law J 2007; 62:(2):399-422
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17632969&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL10967
Hack EI.
Pharmaceutical global marketing practices: increased scrutiny ahead?
Food Drug Law J 2007; 62:(2):343-8
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17632965&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11091
Ilku L, Vizi J.
[Off-label drug prescriptions].
Psychiatr Hung 2007; 22:(1):89-94
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17642123&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11096
Majoras DP.
Food for thought: the FTC and market influences on consumer health.
Food Drug Law J 2007; 62:(2):433-9
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17632972&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11097
Bradshaw ST.
New FDA guidance documents.
Food Drug Law J 2007; 62:(2):429-31
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17632971&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11098
Soller RW, Rice LG, Ambrose PJ.
Disclaimers in dietary supplement print advertising: the bodybuilding category as a model case for change.
Food Drug Law J 2007; 62:(2):375-86
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17632967&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11099
Reiss JB, Levy MC, Hall CR, Wartman GJ.
Your business in court--2006.
Food Drug Law J 2007; 62:(2):305-42
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17632964&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11106
McEwen J, Thompson BR, Purcell PM, Kelly LF, Krauss AS.
Widespread hyoscine hydrobromide toxicity due to contract manufacturer malpractice : the travacalm episode.
Drug Saf 2007; 30:(5):375-8
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17472417&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11127
Fisher MA.
Medicine and Industry: A Necessary but Conflicted Relationship
Perspect Biol Med. 2007 Winter; 50:(1):1-6
http://muse.jhu.edu/login?uri=/journals/perspectives_in_biology_and_medicine/v050/50.1fisher.html
HSL11128
Kassirer JP.
Professional societies and industry support: what is the quid pro quo?
Perspect Biol Med 2007 Win; 50:(1):7-17
http://muse.jhu.edu/login?uri=/journals/perspectives_in_biology_and_medicine/v050/50.1kassirer.html
HSL11129
Epstein RA.
Conflicts of interest in health care: who guards the guardians?
Perspect Biol Med 2007 Win; 50:(1):72-88
http://muse.jhu.edu/login?uri=/journals/perspectives_in_biology_and_medicine/v050/50.1epstein.html
HSL11146
Hawkins LC, Edwards JN, Dargan PI.
Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literature.
Drug Saf 2007; 30:(6):465-79
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17536874&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11184
McCabe C, Tsuchiya A, Claxton K, Raftery J.
Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al.
Int J Technol Assess Health Care 2007 Sum; 23:(3):397-401
http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=1066128
HSL11185
Hauben M, Reich L, DeMicco J, Kim K.
'Extreme duplication' in the US FDA Adverse Events Reporting System database.
Drug Saf 2007; 30:(6):551-4
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17536881&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11244
Golomb BA, McGraw JJ, Evans MA, Dimsdale JE.
Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.
Drug Saf 2007; 30:(8):669-75
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17696579&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11250
Downes-Grainger C.
Prescription for Injury: The Politics of Pharmaceutical Manufacture, Regulation and Prescription
2007
http://www.actionminddrugs.org.uk/index2.html
HSL11294
Grinols EL, Henderson JW.
Replace pharmaceutical patents now.
Pharmacoeconomics 2007; 25:(5):355-63
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17488135&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11315
Glaeske G.
[The limits of economic efficiency--medication provision and 'border violations' through structures and interests].
Z Arztl Fortbild Qualitatssich 2007; 101:(5):347-55
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17711263&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11317
Petros B.
Ethical review of health-related biotechnology research in Africa: a role for the Pan African Bioethics Initiative (PABIN).
Afr J Med Med Sci 2007; 36:Suppl:43-7.
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17703564&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11349
Pearce N.
Adverse Reactions: The Fenoterol Story
Auckland: Auckland University Press 2007
http://web.archive.org/web/20081231211217/http://www.auckland.ac.nz/uoa/aup/book/2007/fenoterol.cfm
HSL11364
Leeman E.
The costs of compliance.
J Am Acad Psychoanal Dyn Psychiatry 2007 Sum; 35:(2):179-87
http://www.atypon-link.com/doi/abs/10.1521/jaap.2007.35.2.179
HSL11376
Berry TR, Wharf-Higgins J, Naylor PJ.
SARS wars: an examination of the quantity and construction of health information in the news media.
Health Commun 2007; 21:(1):35-44
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17461750&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11377
Pinkleton BE, Weintraub Austin E, Cohen M, Miller A, Fitzgerald E.
A statewide evaluation of the effectiveness of media literacy training to prevent tobacco use among adolescents.
Health Commun 2007; 21:(1):23-34
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17461749&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11454
Almenoff JS.
Innovations for the future of pharmacovigilance.
Drug Saf 2007; 30:(7):631-3
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17604419&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11455
Hauben M.
Signal detection in the pharmaceutical industry: integrating clinical and computational approaches.
Drug Saf 2007; 30:(7):627-30
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17604418&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11456
Hand DJ.
Principles of data mining.
Drug Saf 2007; 30:(7):621-2
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17604416&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11457
Kahn SN.
You've found a safety signal--now what?: regulatory implications of industry signal detection activities
Drug Saf. 2007; 30:(7):615-6
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17604414&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
HSL11472
Kavadas C, Katsanis LP, Lebel J.
The effects of risk disclosure and ad involvement on consumers in DTC advertising
Journal of Consumer Marketing 2007; 24:(3):171-179
HSL11521
Hess V.
[Psychochemicals crossing the wall. The introduction of psychoactive pharmaceuticals in the German Democratic Republic--a perspective from the new historiography of drugs].
Medizinhist J 2007; 42:(1):61-84
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17874752
HSL11529
Ferreira G.
Prescription-event monitoring: developments in signal detection.
Drug Saf 2007; 30:(7):639-41
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17604421
HSL11541
Globalization, trade and health: pharmaceutical industry
World Health Organization 2007
http://www.who.int/trade/glossary/story073/en/index.html
HSL11550
Dinan W, Miller D.
Thinker, Faker, Spinner, Spy: Corporate PR and the Assault on Democracy
London: Pluto 2007
http://www.amazon.com/Thinker-Faker-Spinner-Spy-Corporate/dp/0745324444/ref=dp_return_1/102-5869202-0212934?ie=UTF8&n=283155&s=books&qid=1190546386&sr=1-1
HSL11551
Miller D, Dinan W.
A Century of Spin
London: Pluto 2007
http://www.amazon.com/Century-Spin-David-Miller/dp/0745326889/ref=sr_1_1/102-5869202-0212934?ie=UTF8&s=books&qid=1190546694&sr=1-1
HSL11609
Solly M.
'Don't get caught out': pragmatic and discourse features of informational and promotional texts in international healthcare insurance.
Commun Med 2007; 4:(1):27-35
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17714041
HSL11615
Torbenson M, Erlen J.
A quantitative profile of the patent medicine industry in Baltimore from 1863 to 1930.
Pharm Hist 2007; 49:(1):15-27
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17645151
HSL11616
Stakisaitis D, Spokiene I, Juskevicius J, Valuckas KP, Baiardi P.
Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service.
Medicina (Kaunas) 2007; 43:(6):441-6
http://medicina.kmu.lt/0706/0706-01e.pdf
HSL11780
O'Donovan O.
Corporate Colonization of Health Activism? Irish Health Advocacy Organizations' Modes of Engagement with Pharmaceutical Corporations
Int J Health Serv 2007 Oct; 37:(4):711 - 733
http://baywood.metapress.com/openurl.asp?genre=article&id=doi:10.2190/HS.37.4.h
HSL11811
Huberfeld N.
Pharma on the hot seat.
J Health Law 2007 Spr; 40:(2):241-65
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17849829
HSL11861
Aggett PJ.
Criteria for substantiating claims.
Novartis Found Symp 2007; 282:46-53;:
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17913223
HSL11866
Pauwels E
Ethics for Researchers: Facilitating Research Excellence in FP7
Brussels: Governance and Ethics Unit, Science Economy and Society Directorate, European Commission 2007
http://ec.europa.eu/research/science-society/document_library/pdf_06/ethics-for-researchers-040707_en1.pdf
HSL11887
Firmian L, Baudo A.
We'll take care of you
CinemaSalute Srl 2007
http://www.sickpills.com/
HSL11902
Yaros AM.
Attitudes and behaviors of human services students associated with direct-to-consumer advertising (dtca) of prescription drugs.
2007
HSL11919
Olfman S (Ed).
Bipolar Children: Cutting-Edge Controversy, Insights, and Research (Childhood in America)
Westport CT: Praeger Publishers 2007
http://www.praeger.com/catalog/C9730.aspx
HSL11926
Bright RA.
Strategy for surveillance of adverse drug events.
Food Drug Law J 2007; 62:(3):605-16
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17915403
HSL11927
Zigler J, Walsh J, Zigler J.
Medical device reporting: issues with Class III medical devices.
Food Drug Law J 2007; 62:(3):573-80
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17915398
HSL11928
O'Reilly JT.
Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
Food Drug Law J 2007; 62:(3):559-72
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17915397
HSL11929
Tiedt TN.
The drug safety system conundrum.
Food Drug Law J 2007; 62:(3):547-558
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17915396
HSL11930
Jacobson JD, Feigal D.
Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
Food Drug Law J 2007; 62:(3):529-46
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17915395
HSL11931
Cobert B.
Drug safety: a contrarian's point of view.
Food Drug Law J 2007; 62:(3):501-12
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17915392
HSL11932
Schanz SJ.
Pharmaceutical postmarket review: fact or fiction?
Food Drug Law J 2007; 62:(3):493-500
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17915391
HSL11933
Hall RF.
The risk of risk reduction: can postmarket surveillance pose more risk than benefit?
Food Drug Law J 2007; 62:(3):473-92
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17915389
HSL11934
Shea LL, Hanson A, Guglielmetti TM, Levy K.
Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases
Food Drug Law J. 2007;62(3):. 2007; 62:(3):445-72
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=17915388
Page 74 of 144 pages ‹ First < 72 73 74 75 76 > Last ›
